Potential benefits of SGLT2 inhibitors in further specific conditions (i.e., cardiac amyloidosis, grown‐up congenital heart disease and paediatric patients with HF) have been reported in observational studies but need confirmation from prospective trials. The gene discussed is SLC5A2; the disease is cardiac amyloidosis.